Sorafenib (SOR), a frontline hepatocellular carcinoma (HCC) therapeutic, induces ferroptosis through inhibition of solute carrier family 7 member 11 (SLC7A11). This evidence concerns the gene SLC17A1 and hepatocellular carcinoma.